Loading
A phase 2/3 trial of Vibegron in childhood cancers, run by Urovant Sciences GmbH, now recruiting.
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC is a phase 2/3 interventional study registered as NCT05491525 by Urovant Sciences GmbH, with 71 participants planned, started 2022-10-12 and due to reach its primary completion in 2030-03. Interventions recorded: Vibegron.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.